A Dog THC Distribution Study Showed Why Total Radioactivity Should Not Be Reported as Unchanged THC

A 1976 dog experiment found that only part of brain radioactivity after labeled THC represented unchanged THC. Its tissue and subcellular findings therefore cannot be summarized as though every radioactive signal measured active parent drug.

The analytical components were separated

The study compared tolerant and non-tolerant dogs after an intravenous labeled-THC challenge. The abstract identified 46% of brain radioactivity as THC and separately discussed metabolite contributions. Total label and a chemically identified parent-drug fraction answer different questions.

Not every regional difference was significant

Brain-area radioactivity was generally lower in tolerant animals, but only selected regional comparisons reached significance. A broad directional pattern should not be described as a statistically demonstrated decrease in every region. Plasma radioactivity also did not differ significantly between groups.

A subcellular finding suggested rather than proved a mechanism

A lower synaptic-vesicle signal prompted a possible mechanistic interpretation. The authors did not find that the other fraction comparisons explained tolerance. A fraction-associated signal does not independently demonstrate receptor action, subjective effect or functional adaptation.

Interpreting the evidence

For a distribution claim, identify whether the measurement is parent THC, a metabolite or total radioactivity. This animal study does not validate a human brain-to-blood conversion, and its short post-dose sampling cannot establish a complete time course of impairment.

Related reading: interpreting cannabis tolerance claims.

Research reference

Martin BR; Dewey WL; Harris LS; Beckner JS (1976). 3H-delta9-tetrahydrocannabinol tissue and subcellular distribution in the central nervous system and tissue distribution in peripheral organs of tolerant and nontolerant dogs. The Journal of pharmacology and experimental therapeutics. PubMed research record.

This analysis draws on the supplied abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

A 2017 drug-discovery report described APD371, a selective CB2 agonist, maintaining its effect during a five-day rat osteoarthritis-pain protocol. That short preclinical finding is different from established long-term clinical efficacy. The report concerned selection of a development candidate The authors considered receptor efficacy, pharmacokinetics and pharmaceutical properties alongside an oral…

Spread the love

Read Article: APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

A 2021 rat study found sustained pain-response effects with JWH133 while another CB2 agonist lost efficacy after two days under its repeated-treatment protocol. Shared receptor targeting did not establish equal durability. The compounds were compared in a defined model The experiment used chemically induced osteoarthritis and measured pressure responses and…

Spread the love

Read Article: Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

A 2021 review argued that acute neurocognitive responses to cannabis vary with biological, pharmacological and exposure-related factors. A product label or use-frequency category alone cannot capture all the determinants discussed. The review considered interacting sources of variation It discussed brain-network activity, formulation, use frequency and differences between therapeutic and recreational…

Spread the love

Read Article: An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us